ELOX — Eloxx Pharmaceuticals Share News
0.000.00%
Last trade - 00:00NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 02:19 PM
Brief: Eloxx Pharmaceuticals Provides ELX-02 And ZKN-013 Program Updates
Brief: Eloxx Pharmaceuticals Confirms That Alport Syndrome Patients Treated With Elx-02 In Phase 2 Study Had Improvement
Brief: Eloxx Pharmaceuticals Inc Reports Results In All Patients Treated With Elx-02 In Phase 2 Clinical Study For Alport Syndrome
Eloxx Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Eloxx Pharmaceuticals Inc expected to post a loss of $1.54 a share - Earnings Preview
Brief: Eloxx Pharmaceuticals Granted Extension By Nasdaq To Regain Compliance
Brief: Eloxx Pharmaceuticals Announces Final Data Assessment From Phase 2 Combination Clinical Trial Of ELX-02
Brief: Eloxx Pharmaceuticals Granted Extension By Nasdaq To Regain Compliance With The Market Value Of Listed Securities Continued Listing Requirement
Brief: Atossa Appoints Life Sciences Financial And Operations Industry Veteran Greg Weaver As Chief Financial Officer
Brief: Eloxx Pharmaceuticals Inc- Entered Into A Sales Agreement With Oppenheimer & Co. Inc
Brief: Eloxx Pharmaceuticals Intends To Advance ELX-02 Into Pivotal Trial For The Treatment Of Alport Syndrome With Nonsense Mutations
Brief: Eloxx Pharmaceuticals Reports First Quarter 2023 Financial And Operating Results And Provides Business Update
Eloxx Pharmaceuticals Inc expected to post a loss of $2.55 a share - Earnings Preview
Brief: Eloxx Pharma Gets FDA Clearance To Begin Single Ascending Dose Study Of ZKN-013
Eloxx Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Brief: Eloxx Pharmaceuticals Announces Submission Of Investigational New Drug Application For Zkn-013
Eloxx Pharmaceuticals Inc expected to post a loss of $2.97 a share - Earnings Preview
Brief: Eloxx Pharmaceuticals Announces Initiation Of Phase 2 Clinical Study Evaluating Elx-02 For Treatment Of Alport Syndrome With First Patient Dosed